Cargando…

Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers

Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Jessica M., Perelson, Alan S., Li, Jonathan Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682162/
https://www.ncbi.nlm.nih.gov/pubmed/31339888
http://dx.doi.org/10.1371/journal.pcbi.1007229
_version_ 1783441845835005952
author Conway, Jessica M.
Perelson, Alan S.
Li, Jonathan Z.
author_facet Conway, Jessica M.
Perelson, Alan S.
Li, Jonathan Z.
author_sort Conway, Jessica M.
collection PubMed
description Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes years. We present a stochastic mathematical model to gain insight into these post-treatment dynamics, specifically characterizing the dynamics of short term viral rebounds (≤ 60 days). Li et al. (2016) report that the size of the expressed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time between ART suspension and viral rebound to detectable levels. We incorporate this information and viral rebound times to parametrize our model. We then investigate insights offered by our model into the underlying dynamics of the latent reservoir. In particular, we refine previous estimates of viral recrudescence after ART interruption by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of once every 2-4 days. Our parametrized model can be used to aid in design of clinical trials to study viral dynamics following analytic treatment interruption. We show how to derive informative personalized testing frequencies from our model and offer a proof-of-concept example. Our results represent first steps towards a model that can make predictions on a person living with HIV (PLWH)’s rebound time distribution based on biomarkers, and help identify PLWH with long viral rebound delays.
format Online
Article
Text
id pubmed-6682162
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66821622019-08-15 Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers Conway, Jessica M. Perelson, Alan S. Li, Jonathan Z. PLoS Comput Biol Research Article Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes years. We present a stochastic mathematical model to gain insight into these post-treatment dynamics, specifically characterizing the dynamics of short term viral rebounds (≤ 60 days). Li et al. (2016) report that the size of the expressed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time between ART suspension and viral rebound to detectable levels. We incorporate this information and viral rebound times to parametrize our model. We then investigate insights offered by our model into the underlying dynamics of the latent reservoir. In particular, we refine previous estimates of viral recrudescence after ART interruption by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of once every 2-4 days. Our parametrized model can be used to aid in design of clinical trials to study viral dynamics following analytic treatment interruption. We show how to derive informative personalized testing frequencies from our model and offer a proof-of-concept example. Our results represent first steps towards a model that can make predictions on a person living with HIV (PLWH)’s rebound time distribution based on biomarkers, and help identify PLWH with long viral rebound delays. Public Library of Science 2019-07-24 /pmc/articles/PMC6682162/ /pubmed/31339888 http://dx.doi.org/10.1371/journal.pcbi.1007229 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Conway, Jessica M.
Perelson, Alan S.
Li, Jonathan Z.
Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title_full Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title_fullStr Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title_full_unstemmed Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title_short Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
title_sort predictions of time to hiv viral rebound following art suspension that incorporate personal biomarkers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682162/
https://www.ncbi.nlm.nih.gov/pubmed/31339888
http://dx.doi.org/10.1371/journal.pcbi.1007229
work_keys_str_mv AT conwayjessicam predictionsoftimetohivviralreboundfollowingartsuspensionthatincorporatepersonalbiomarkers
AT perelsonalans predictionsoftimetohivviralreboundfollowingartsuspensionthatincorporatepersonalbiomarkers
AT lijonathanz predictionsoftimetohivviralreboundfollowingartsuspensionthatincorporatepersonalbiomarkers